WCLC, TORONTO, 23-26 September 2018

Impact of afatinib dosing on safety and effectiveness in real-world patients with EGFR mutation-positive advanced NSCLC (RealGiDo study)

Balazs Halmos, Eng-Huat Tan, Ross Soo, Jacques Cadranel, Min Ki Lee, Pascal Foucher, Te-Chun Hsia, Maximilian Hochmair, Frank Griesinger, Toyoaki Hida, Edward S. Kim, Barbara Melosky, Angela Märten, Enric Carcereny

Halmos_RealGiDo WCLC


Learn more about the science behind this poster in the videos, papers and other materials below.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Yang JC, et al. Ann Oncol. 2016 Nov;27(11):2103-2110

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations

Sequist LV, et al. J Clin Oncol. 2013 Sep 20;31(27):3327-34


In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

In Switzerland, Afatinib is approved as monotherapy for patients with non-small cell lung cancer (NSCLC, stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable.

The information contained herein does not necessarily reflect the content of the approved Canadian product monograph.